Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation.
Over the last 20 years, immunosuppression protocols in liver transplant patients have been based on calcineurin inhibitors, such as cyclosporine (CsA). Currently, there are three outstanding clinical issues related to the use of CsA in the liver transplant setting that merit further attention: (1) dose adjustment according to 2-hour postdose (instead of trough) concentrations to improve efficacy and safety, (2) possible synergistic effect between CsA and antiviral treatments for recurrent posttransplant hepatitis C infection, and (3) preliminary results showing favorable outcomes after liver transplantation in HIV-positive patients receiving antiviral therapy.
Casanovas Taltavull
T
T
Liver Transplant Unit, Hospital Universitario de Belvitge, L'Hospitalet de Llobregat, Barcelona, Spain. t.casanovas@csub.scs.es
D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid